Format

Send to

Choose Destination
Mol Genet Metab. 2018 Feb;123(2):135-139. doi: 10.1016/j.ymgme.2017.10.011. Epub 2017 Oct 23.

Tandem mass spectrometry assay of β-glucocerebrosidase activity in dried blood spots eliminates false positives detected in fluorescence assay.

Author information

1
Sanofi, P. O. Box 9322, Framingham, MA 01701, USA.
2
Columbia University Medical Center, Neurological Institute, 710 West, 168th street, New York, NY 10032, USA.
3
Sanofi, P. O. Box 9322, Framingham, MA 01701, USA; Great Ormond Street Hospital for Children, NHS Foundation Trust, Great Ormond Street, London, WC1N 3JH, UK.
4
Division of Human Genetics, Cincinnati Children's Hospital Medical Center and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
5
Department of Neurology & Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada; Department of Human Genetics, McGill University, Montreal, QC, Canada.
6
Department of Pediatrics and Medicine, Columbia University Medical Center, New York, NY, USA.
7
Sanofi, P. O. Box 9322, Framingham, MA 01701, USA. Electronic address: petra.oliva@sanofi.com.

Abstract

Deficiency of β-Glucocerebrosidase (GBA) activity causes Gaucher Disease (GD). GD can be diagnosed by measuring GBA activity (Beutler and Kuhl, 1990). In this study, we assayed dried blood spots from a cohort (n=528) enriched for GBA mutation carriers (n=78) and GD patients (n=18) using both the tandem mass spectrometry (MS/MS) and fluorescence assays and their respective synthetic substrates. The MS/MS assay differentiated normal controls, which included GBA mutation carriers, from GD patients with no overlap. The fluorescence assay did not always differentiate normal controls including GBA mutation carriers from GD patients and false positives were observed. The MS/MS assay improved specificity compared to the fluorescence assay.

KEYWORDS:

Dried blood spots (DBS); Gaucher disease (GD); Glucocerebroside; Lysosomal storage disorder (LSD); Newborn screening (NBS); β-Glucocerebrosidase (GBA)

PMID:
29100779
PMCID:
PMC5808899
[Available on 2019-02-01]
DOI:
10.1016/j.ymgme.2017.10.011
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center